Secretariat draft
21 June 1993
realistic level. The response to the MMC noted that it was likely that the
Review would conclude that CDC should no longer maintain a separate RNR
target. There is no reason to change this conclusion. While CDC will
continue to exploit its capacity to invest successfully in this sector, it
is not considered any longer appropriate to single out the RNR sector for
a quantified target.
6.10 More generally, the appropriate sectors for CDC to invest in will be
determined by the needs of the countries in which it operates, taking
account of the balancing of risk across sectors. We do not therefore make
any specic recommendation about the sectoral balance of the programme.
Country targets
6.11 The countries in which CDC is currently authorised to operate are
indicated in Annex 0. Of these, CDC agreed in 1984 to consult ODA before
considering new investments in Hong Kong, Singapore, Cyprus, Gibraltar,
Malta and Trinidad, and before initiating activity in Rwanda, Tunisia and
Zaire.
6.12
Section 2 above considered CDC's role and the rationale for its
status as a public sector body. In essence this is to operate in countries
where private direct investors are reluctant to go, and to demonstrate to
them and to developing country governments, the possibility of sucessful
direct investment in these countries. CDC should not displace private
investment but should endevour to attract private sector co-investors.
6.13 This role has hitherto been seen as being fulfilled by concentrating
on poor countries: CDC has therefore been set a target for the level of
commitments in these countries. This is currently to invest 60% in
countries with a per capita income of $800 in 1983 (roughly the upper
limit of IDA eligibility which now (1991) stands at $1235 per capita).
Since 1986 CDC has exceeded the target assisted by extending its
operations to India and Pakistan. Recently, poor countries have accounted
for nearly 70 per cent of investment.
4
Page 60Page 61
No comments yet.
Private notes are available after approval.